Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT study of intravenous exenatide in healthy volunteers
NL-OMON43489Active, not recruiting
- Sponsor
- Intarcia Therapeutics
- Start
- Jan 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Intarcia Therapeutics. Primary endpoints: Target exenatide concentration at end of infusion and Effect on QTc interval relative to ICH E14 threshold. Started Jan 2016; status: active, not recruiting.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON43489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43489.